TrialAdvances in therapy2026

Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn's Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial.

Stefan Schreiber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.